Guidelines currently recommend shared decision-making between males and their health care clinicians regarding prostate cancer screening using prostate-specific antigen (PSA), taking into consideration patient age and life expectancy.1 However, it is unclear the extent to which life expectancy is associated with screening practices among older males. This evidence concerns the gene KLK3 and Familial prostate cancer.